Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial

Annals of Internal Medicine

Volumn 130, Issue 6, 1999, Pages 487-495

  Malmstrom, Kerstin ^a   Rodriguez Gomez, Guillermo ^a   Guerra, Jeremias ^a   Villaran, Cesar ^a   Piñeiro, Andres ^a   Wei, Lynn X ^b   Seidenberg, Beth C ^a   Reiss, Theodore F ^a  

^a Department of Biostatistics ^*

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; SALBUTAMOL; THEOPHYLLINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INHALER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033574195     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-6-199903160-00005     Document Type: Article

References (33)

1. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: U.S. Dept of Health and Human Services, National Institutes of Health; February 1997.
2. Dolovich M. Influence and inhalation technique on response and compliance. European Respiratory Review 1995;5:166-9
3. Newhouse MT. Aerosol therapy of asthma in adults and children: role of MDI, DPI, holding chambers and nebulizers. Atemwegs-und-Lungenkrankheiten 1994;20(Suppl 5):268-76.
4. Lewis RA, Austen KF, Soberman RJ. Leukotriene and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645-55.
5. 4-receptor antagonist, in subjects with bronchial asthma. Accolate Asthma Trialists Group. Am J Respir Crit Care Med. 1994;150:618-23.
6. Grossman J, Faiferman I, Dubb JW, Tompson DJ, Busse W, Bronsky E, et al. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study with pranlukast, a novel leukotriene receptor antagonist. J Asthma. 1997;34:321-8.
7. Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol. 1996;98:528-34.
8. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma, A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996;275:931-6.
9. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1995;73:191-201.
10. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol. 1998;102:50-6.
11. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg BC, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998;158: 1213-20.
12. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6-to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998;297: 1181-6.
13. Botto A, Malmstrom K, Lu S, Zhang J, Reiss TF. Centralized spirometry quality control lowers the variability in multicenter asthma clinical trials [Abstract]. Am J Respir Crit Care Med. 1997;155:A893.
14. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J. 1997;10:646-51.
15. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Miller TK. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76-83.
16. Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmaco Economics. 1993;4:345-52.
17. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46:1417-32.
18. Dunnett CW, Tamhane AC. Comparisons between a new drug and active and placebo controls in an efficacy clinical trial. Stat Med. 1992;11:1057-63.
19. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther. 1997;62:556-61.
20. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J. 1998;11:1232-9.
21. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, et al. Issues in the use of inhaled glucocorticosteroids. The Asthma Clinical Research Network. Am J Respir Crit Care Med. 1996;153(6 Pt 1): 1739-48.
22. In KH, Asano K, Beier D. Grobholz J, Finn PW, Silverman EK, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 1997;99:1130-7.
23. 2-agonists [Abstract]. Eur Respir J. 1997;10:419s, P2716.
24. Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med. 1993;119: 329-35.
25. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med. 1994; 154:1349-52.
26. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994;331:700-5.
27. Nattel S, Rangno RE, Van Loon G. Mechanism of propranolol withdrawal phenomena. Circulation. 1979;59:1158-64.
28. Bousquet J, Chanez P, Vignola AM, Lacoste JY, Michel FB. Eosinophil inflammation in asthma. Am J Respir Crit Care Med. 1994;150:933-8.
29. Trigg O, Manolitsas ND, Wang J, Claderon MA, McAulay A, Jordan SE, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med. 1994;150:17-22.
30. Leff JA, Pizzichini E, Efthimiadis A, Boulet LP, Wei LX, Weinland DE, et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial [Abstract]. Am J Respir Crit Care Med. 1997:155:A977.
31. Cumming RG, Mitchell P, Leader SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8-14.
32. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88:373-81.
33. Reiss TF, White R, Noonan G. Korenblat P, Hess J, Shingo S. Montelukast (MK-0476), a CysLT1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment. Montelukast Study Group [Abstract], Eur Respir J. 1997;10:437s, P2808.